Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9668 crossover LPS airway inflammation study in healthy volunteers
2007-004584-22Phase 2Unknown
- Sponsor
- AstraZeneca
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alvelestat in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoints: Change in neutrophil numbers in induced sputum and Change in neutrophil elastase activity in induced sputum. Status: unknown.
02
Drugs
alvelestat
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2007-004584-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004584-22.